Skip to main content

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Publication ,  Journal Article
Hammonds, J; Chen, X; Fouts, T; DeVico, A; Montefiori, D; Spearman, P
Published in: J Virol
December 2005

A major challenge for the development of an effective HIV vaccine is to elicit neutralizing antibodies against a broad array of primary isolates. Monomeric gp120-based vaccine approaches have not been successful in inducing this type of response, prompting a number of approaches designed to recreate the native glycoprotein complex that exists on the viral membrane. Gag-Env pseudovirions are noninfectious viruslike particles that recreate the native envelope glycoprotein structure and have the potential to generate neutralizing antibody responses against primary isolates. In this study, an inducible cell line was created in order to generate Gag-Env pseudovirions for examination of neutralizing antibody responses in guinea pigs. Unadjuvanted pseudovirions generated relatively weak anti-gp120 responses, while the use of a block copolymer water-in-oil emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotides resulted in high levels of antibodies that bind to gp120. Sera from immunized animals neutralized a panel of human immunodeficiency virus (HIV) type 1 primary isolate viruses at titers that were significantly higher than that of the corresponding monomeric gp120 protein. Interpretation of these results was complicated by the occurrence of neutralizing antibodies directed against cellular (non-envelope protein) components of the pseudovirion. However, a major component of the pseudovirion-elicited antibody response was directed specifically against the HIV envelope. These results provide support for the role of pseudovirion-based vaccines in generating neutralizing antibodies against primary isolates of HIV and highlight the potential confounding role of antibodies directed at non-envelope cell surface components.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

December 2005

Volume

79

Issue

23

Start / End Page

14804 / 14814

Location

United States

Related Subject Headings

  • Virology
  • Virion
  • Vaccines, DNA
  • Tumor Cells, Cultured
  • Peptide Fragments
  • Neutralization Tests
  • Immunization
  • Humans
  • HIV-1
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hammonds, J., Chen, X., Fouts, T., DeVico, A., Montefiori, D., & Spearman, P. (2005). Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol, 79(23), 14804–14814. https://doi.org/10.1128/JVI.79.23.14804-14814.2005
Hammonds, Jason, Xuemin Chen, Timothy Fouts, Anthony DeVico, David Montefiori, and Paul Spearman. “Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.J Virol 79, no. 23 (December 2005): 14804–14. https://doi.org/10.1128/JVI.79.23.14804-14814.2005.
Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol. 2005 Dec;79(23):14804–14.
Hammonds, Jason, et al. “Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.J Virol, vol. 79, no. 23, Dec. 2005, pp. 14804–14. Pubmed, doi:10.1128/JVI.79.23.14804-14814.2005.
Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol. 2005 Dec;79(23):14804–14814.

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

December 2005

Volume

79

Issue

23

Start / End Page

14804 / 14814

Location

United States

Related Subject Headings

  • Virology
  • Virion
  • Vaccines, DNA
  • Tumor Cells, Cultured
  • Peptide Fragments
  • Neutralization Tests
  • Immunization
  • Humans
  • HIV-1
  • HIV Infections